Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL‐directed chemotherapy combined with continuous imatinib |
| |
| Authors: | Alexey Maschan Galina Novichkova Natalia Miakova Marina Persiantseva |
| |
| Affiliation: | Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia |
| |
| Abstract: | An 11‐year‐old male was diagnosed with chronic‐phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon‐α2b and low‐dose cytarabine. In 6 years, he progressed to lymphoid blast crisis and received induction chemotherapy with prednisolone, vincristine, daunorubicin, and l ‐asparaginase concomitantly with imatinib 400 mg/day, and continuation with vincristine + prednisolone, cytarabine + etoposide, vincristine + l ‐asparaginase, cyclophosphamide + etoposide, and 6‐mercaptopurine + methotrexate. Complete molecular response (MR) was achieved and therapy was continued with imatinib 800 mg/day. He relapsed to chronic‐phase CML after interruption of imatinib and regained MR after its restart. The patient is alive 17.5 years after CML diagnosis and 11.5 years after lymphoid blast crisis. |
| |
| Keywords: | chemotherapy CML imatinib lymphoid blast crisis |
|
|
